CervoMed Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRVO research report →
Range $7 – $7
Price Chart
About the company
CervoMed Inc. , a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.
- CEO
- John J. Alam
- IPO
- 2008
- Employees
- 15
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on CRVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.92M
- P/E
- -1.04
- PEG
- 0.05
- P/S
- 95.87
- P/B
- 1.49
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -9661.43%
- Net Margin
- -9408.76%
- ROE
- -156.02%
- ROIC
- -135.73%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-28,294,877
- Net Income
- $-26,966,367-65.5%
- EPS
- $-2.98-47.5%
- OCF Growth
- -41.9%
- FCF Growth
- -41.9%
- 52W High
- $10.00
- 52W Low
- $2.13
- 50D MA
- $2.68
- 200D MA
- $4.00
- Beta
- -4.31
- RSI (14)
- 76
- Avg Volume
- 337.45K
No earnings-call transcripts are available for CRVO yet.
- Free Float
- 65.5%
- Shares Outstanding
- 9.26M
- Float Shares
- 6.06M
of shares held by institutions
36 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Woodline Partners LP | 688.99K | ▲ 688.99K |
| Vanguard Group Inc | 354.95K | ▲ 11.49K |
| Vanguard Capital Management LLC | 316.20K | 0 |
| Sabby Management, LLC | 248.88K | ▲ 248.88K |
| Geode Capital Management, LLC | 66.92K | ▼ 7.45K |
| Blackrock, Inc. | 53.84K | ▲ 2.19K |
| Byrne Asset Management LLC | 51.25K | ▲ 36.55K |
| Citizens Financial Group Inc/Ri | 37.48K | 0 |
| Vanguard Fiduciary Trust Co | 36.15K | 0 |
| Jane Street Group, LLC | 32.23K | ▲ 13.98K |
| Thompson Davis & Co., Inc. | 29.75K | ▲ 19.75K |
| Savvy Advisors, Inc. | 25.92K | 0 |
Held by 23 ETFs
Biggest fund positions in CRVO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | BOGER JOSHUA S | buy | 955,414 |
| Jun 11, 26 | BOGER JOSHUA S | buy | 955,414 |
| Jun 11, 26 | BOGER JOSHUA S | buy | 955,414 |
| Jun 8, 26 | ZAVRL FRANK | other | 8,150 |
| Jun 8, 26 | Sabbagh Marwan | other | 8,150 |
| Jun 8, 26 | Quigley David | other | 8,150 |
| Jun 8, 26 | Poulton Jeffrey V. | other | 8,150 |
| Jun 8, 26 | Hollingsworth Jane H | other | 8,150 |
| Jun 8, 26 | Gregoire Sylvie | other | 8,150 |
| Jun 8, 26 | BOGER JOSHUA S | other | 8,150 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRVO coverage
Recent articles, reports, and earnings notes.
No research on CRVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRVO report →CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright
defenseworld.net · Oct 5
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages
defenseworld.net · Oct 3
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
globenewswire.com · Sep 28
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
globenewswire.com · Sep 22
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
globenewswire.com · Sep 10
CervoMed to Participate in September Investor Conferences
globenewswire.com · Sep 8
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com · Aug 10
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
globenewswire.com · Aug 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.